BlinkLab (ASX:BB1) said the firm and Mental Care Group expanded the Attention Deficit and Hyperactivity Disorder (ADHD) clinical study from one to five European clinical sites to "better capture the clinical heterogeneity of ADHD and ensure broader generalizability," according to a Friday Australian bourse filing.
Including the initial group, the study is estimated to report data from around 300 participants by the end of the year.
The new sites have been recently onboarded and will actively participate in the study enrollment.
The data from the study will form a critical part of BlinkLab's clinical evidence package under the European regulatory framework.
Two clinical sites are actively recruiting participants in the pilot phase of its US autism trial, PriMED Clinical Research in Ohio and North Shore Pediatric Therapy in Illinois. Two more sites are fully onboarded for the main phase of the study, the University of Nebraska Medical Center in Nebraska and the Southwest Autism Research and Resource Center in Arizona.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。